We propose that this change in binding enhanced the inhibitory effects of CD33 on amyloid plaque degradation, and together with other genetic, epigenetic, and environmental factors, could predispose to the accumulation of amyloid plaques and the onset of AD pathology. The gene discussed is CD33; the disease is amyloidosis.